Collectively, the emerging premise is that heparanase expressed by tumor cells, innate immune cells, activated endothelial cells, and other cells of the tumor microenvironment is a master regulator of the aggressive phenotype of cancer, an important contributor to the poor outcome of cancer patients, and a prime target for therapy. This evidence concerns the gene HPSE and neoplasm.